2024-513299-17-00招募中4 期
Stopping anti-TNF treatment in Crohn's and Colitis patients in remission
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- Region Skane
- 入组人数
- 350
- 试验地点
- 4
- 主要终点
- The proportion of patients that relapses, as defined by symptomatic scoring in combination with endoscopy, at 12 and 24 months after discontinuation of anti-TNF treatment with identification of factors at study-start that correlate positively or negatively with the event of relapse.
研究概览
简要总结
The aim is to identify clinical and biological markers that offer guidance as to which patients successfully may discontinue maintenance anti-TNF treatment, and which patients on the contrary need to continue treatment over an extended period of time in order to remain in remission.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •For patients with ulcerative colitis: • Diagnosis: Ulcerative colitis • Age 18-80 years. • Male or female. • IFX or ADA treatment since >12 months; last 3 doses at the same dose and interval. If the patient is on a biosimilar-infliximab the patient must have received at least 3 doses, and at the same dose and interval. • SCCAI score of ≤
- •Endoscopic Baron score of 0-
- •The most inflamed part in the rectum/ sigmoid colon is evaluated. A minimum of 40 cm of the colon should be examined.
- •For patients with Crohn's disease: • Diagnosis: Crohn's disease • Age 18-80 years. • Male or female. • IFX or ADA treatment since >12 months; last 3 doses at the same dose and interval. If the patient is on a biosimilar-infliximab the patient must have received at least 3 doses, and at the same dose and interval. • Simplified HBI (sHBI; abdominal palpation excluded) score of ≤
- •Simplified Endoscopic Score for CD (SES-CD) of ≤4 and no ulcer ≥5 mm other than a potential anastomotic ulcer (ie apthous ulcers allowed). • F-calprotectin <200 mg/kg (PhiCal) or <350 mg/kg (Buhlmann).
排除标准
- •Corticosteroid (rectal or systemic) or rectal 5-ASA treatment during the last 6 months.
- •For patients with ulcerative colitis: Colonic resection.
- •For patients with Crohn's disease: Documented engagement/inflammation of the small bowel proximally of a level of 50 cm from the ileocecal valve. Any examination modality is accepted, and a current/new small intestinal examination is not required. A limited number of small (<5 mm) lesions on capsule endoscopy allowed. Colonic surgery with removal of more than half of the transverse colon.
结局指标
主要结局
The proportion of patients that relapses, as defined by symptomatic scoring in combination with endoscopy, at 12 and 24 months after discontinuation of anti-TNF treatment with identification of factors at study-start that correlate positively or negatively with the event of relapse.
The proportion of patients that relapses, as defined by symptomatic scoring in combination with endoscopy, at 12 and 24 months after discontinuation of anti-TNF treatment with identification of factors at study-start that correlate positively or negatively with the event of relapse.
次要结局
- Endoscopic scores at 12 and 24 months among those who relapsed compared to those who remained in remission.
- Fecal calprotectin levels at 12 and 24 months among those who relapsed compared to those who remained in remission.
- Fecal calprotectin levels at study start among ulcerative colitis patients who relapsed compared to those who remained in remission.
- The rate of relapse among ulcerative colitis patients with the following fecal calprotectin level ranges (<30 mg/kg for Calpro [C] and <60 mg/kg for Buhlmann [B]; 30-99 mg/kg C and 60-199 mg/kg B; 100-299 mg/kg C and 200-599 mg/kg B; ≥300 mg/kg C and ≥600 mg/kg B.
- The optimal fecal calprotectin level cut-off with regards to sensitivity and specificity for relapse, for ulcerative colitis and Crohn's disease patients, respectively.
- Trough concentrations of infliximab and adalimumab among those who relapsed compared to those who remained in remission.
- The rate of relapse among those with undetectable infliximab or adalimumab trough concentrations, those with 0.5-2.9 ug/ml, 3.0-7.0 ug/ml, >7.0 ug/ml for infliximab, and ≥10.0 ug/ml for adalimumab.
- The optimal trough concentration cut-off with regards to sensitivity and specificity for relapse, for infliximab and adalimumab, respectively.
- Area under the infliximab or adalimumab concentration curve during the last therapy cycle among those who relapsed compared to those who remained in remission.
- Presence of anti-drug antibodies among those who relapsed compared to those who remained in remission.
- The rate of relapse among those with anti-drug antibodies versus those without.
- Time to relapse among those who relapse, comparing ADA versus IFX treated and UC versus CD.
- The level of gut microbiota dysbiosis among those who relapsed compared to those who remained in remission.
- The rate of relapse among those with a dysbiosis score of 1, 2-3, and 4-5, respectively.
- Correlation analyses of genes showing high versus low expression in mucosal biopsies and blood samples, with the event of relapse.
- Correlation analyses of gene-variants with the event of relapse.
- Additional factors that will be correlated with relapse rates: Endoscopic scores; corticosteroid use between 12 and 6 months before baseline; previous anti-TNF treatment; dose intensification of anti-TNF treatment; mono- versus concomitant immunomodulatortreatment; previously maximal inflammatory extent (Montreal classification); disease duration; extraintestinal manifestations; gender; smoking; hemoglobin; white blood cell count; platelet count; CRP; and histology/immunohistochemistry.
研究者
Jan Marsal
Scientific
Region Skane
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
1 期
An investigational study to assess the safety and effectiveness of continuing existing 5-ASA medication versus stopping it.Inactive Crohn’s DiseaseEUCTR2018-001382-17-GBAlimentiv Inc1,580
进行中（未招募）
1 期
Anti-TNF discontinuation in patients with inflammatory bowel diseaseInflammatory bowel diseaseMedDRA version: 19.0Level: LLTClassification code 10021973Term: Inflammatory bowel disease NOSSystem Organ Class: 100000004856EUCTR2015-001410-10-ESFundación de Investigación Biomédica Hospital Universitario de la Princesa300
已完成
不适用
Withdrawal of immunomodulator in Crohn's disease treated with adalimumab and immnomodulator : a multicenter randomized trial(Diamond2 study).Crohn`s diseaseJPRN-UMIN000009596Department of Internal Medicine, School of Medicine, Keio University200
进行中（未招募）
不适用
Treatment of Crohn’s disease-associated refractory diarrhoea with octreotide LARAn open pilot studyCrohn Disease refractory diarrhoeaMedDRA version: 12.1Level: LLTClassification code 10066533Term: Diarrhea recurrentEUCTR2010-023347-14-BEGastroenterology CHC Liege
已完成
3 期
Surgical Closure vs Anti-TNF in the Treatment of Perianal Fistulas in Crohn's Disease (PISA-II): a Comprehensive Cohort DesignPerianal FistulaCrohn DiseaseNCT06441526Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)94